Genetic testing, known as DNA testing, allows geneticists to determine bloodlines and diagnose genetic diseases. With the advent of next-generation sequencing (NGS) technologies, whole exome sequencing (WES) is widely used as a cost-effective and accurate method of genetic testing.
Whole exome sequencing (WES) is a sequencing method that employs high-throughput sequencing of exon regions of more than 20,000 genes per individual, that are enriched through sequence capture technology. WES targets all protein-coding regions (~1% of the whole genome) responsible for 85% of known disease-causing variants. It provides molecular diagnosis of genetic diseases and enables the exploration of novel mutations and new pathogenic mechanisms. Compared to whole genome sequencing, WES has the advantage of a greater sequencing depth and delivers more effective data.
For patients with symptoms of genetic disorders, clinical exome sequencing plays an important role in quickly identifying potential variants. Clinical exome sequencing offers a one-step solution for challenging issues, such as diagnosing patients with genetic heterogeneity or atypical presentation, where it is unclear which genes cause specific genetic conditions. The accuracy of clinical-grade sequencing at Novogene is ensured by standardizing each testing step, while the whole process is strictly quality-controlled. Clinical whole exome sequencing at Novogene is validated and performed in our CLIA/CAP/ISO17025 laboratories to achieve the high standards of clinical-grade sequencing, thereby providing precise diagnosis.
We accept whole blood, buccal swab, saliva, and extracted DNA (from whole blood, Buccal swabs, or saliva) for germline WES.
Novogene Buccal Cell Kit
Gentra Puregene Buccal Cell Kit
DNA Genotek ORAcollect•Dx OCD100/100A
Clinical Laboratory Improvement Amendments (CLIA) certified,
CLIA # 05D2146243
The College of American Pathologists (CAP) Accredited,
CAP # 9043632
NovoPMTM 2.0 – A comprehensive somatic tumor profiling panel that analyzes 484 genes for clinically important alterations at the DNA level. These genes are relevant for the diagnosis and/or treatment of various solid tumors according to NCCN guidelines and the medical literature.
This assay applies the power of next-generation sequencing (NGS) to gene expression profiling of typical clinical samples. Based on the TruSeq RNA Exome Library Prep Kit and Novogene’s in-house bioinformatics pipelines, it provides robust and comprehensive transcriptomic analysis of human RNA isolated from FFPE and other low-quality clinical samples.
The field is required.